Fig. 4

Univariate regression models of complications vs. age- and duration-adjusted LW-1 levels (mean ± SD) across treatment groups at DCCT closeout. MA microaneurysms, AER albumin excretion rates, NCV/ANS nerve conduction velocity/autonomic nervous system, NS nonsignificant (P > 0.05). Analysis was limited to those with no respective complication at DCCT baseline (excluding 10 subjects with AER > 40, 19 with confirmed clinical neuropathy, and the secondary cohort for sustained ≥3 MA). Indices of retinopathy, microaneurysms, nephropathy and neuropathy were quantified as previously described [19]. ‡ P value is from a Likelihood Ratio test (LRT) between the respective reduced model and the full model